Louisiana State Employees Retirement System Purchases Shares of 37,100 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Louisiana State Employees Retirement System purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 37,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,371,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its position in Halozyme Therapeutics by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 13,335,155 shares of the biopharmaceutical company’s stock valued at $527,273,000 after purchasing an additional 38,342 shares during the last quarter. Artisan Partners Limited Partnership raised its position in Halozyme Therapeutics by 3.4% during the 3rd quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock valued at $294,632,000 after purchasing an additional 253,363 shares during the last quarter. Snyder Capital Management L P raised its position in Halozyme Therapeutics by 7.8% during the 1st quarter. Snyder Capital Management L P now owns 4,295,184 shares of the biopharmaceutical company’s stock valued at $164,033,000 after purchasing an additional 311,370 shares during the last quarter. Macquarie Group Ltd. raised its position in Halozyme Therapeutics by 22.8% during the 1st quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock valued at $122,226,000 after purchasing an additional 595,220 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Halozyme Therapeutics by 4.6% during the 1st quarter. Geode Capital Management LLC now owns 2,631,387 shares of the biopharmaceutical company’s stock valued at $100,493,000 after purchasing an additional 116,290 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

HALO has been the subject of several research reports. Morgan Stanley decreased their target price on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating for the company in a research report on Tuesday, December 26th. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. TD Cowen started coverage on Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target on the stock. Benchmark restated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. Finally, The Goldman Sachs Group cut their price target on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, January 18th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $53.29.

Halozyme Therapeutics Stock Up 2.2 %

Halozyme Therapeutics stock opened at $38.64 on Monday. The firm has a market cap of $4.91 billion, a price-to-earnings ratio of 18.31, a PEG ratio of 0.45 and a beta of 1.25. The stock has a fifty day simple moving average of $39.56 and a two-hundred day simple moving average of $37.77. Halozyme Therapeutics, Inc. has a 12 month low of $29.85 and a 12 month high of $45.00. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The firm had revenue of $230.04 million during the quarter, compared to the consensus estimate of $235.25 million. Equities analysts predict that Halozyme Therapeutics, Inc. will post 3.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at $6,519,075.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 30,000 shares of company stock valued at $1,196,800 over the last 90 days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.